Question for written answer E-003507/2021
to the Commission
Rule 138
Véronique Trillet-Lenoir (Renew)

Subject: Availability of Trodelvy for European triple negative breast cancer patients

Since April 2020, the US laboratory Gilead has marketed a so-called triple negative breast cancer treatment in the United States called Trodelvy.

This innovative medicine doubles the median survival time for patients compared to traditional chemotherapy.

At this stage, the US authorities, citing low production capacity, have announced that this medicine can no longer be made available to European patients.

1. Can the Commission say on which date the European Medicines Agency plans to publish the emergency marketing authorisation for this medicine?

2. What options is the Commission considering to ensure that European patients have access to this medicine?

3. Could a voluntary licence be granted so that an industrial partnership could be formed to produce this medicine in Europe?